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Scale down or bench scale models (SDM) are critical for the development of biologics in that they are used in all 
phases of process development.  SDM’s are used during early clinical campaigns to select the final clone for 
clinical manufacturing and for optimization and characterization to support market authorization.  It is imperative 
that the SDM be predictive of manufacturing scale in order to provide a robust, consistent, and well-understood 
process.  During commercial process development, statistical methods are used to qualify the SDM, specific to 
the cell line and commercial process.  SDM qualification can be done at this time due to the increased amount 
of data at both the bench and commercial scale to support equivalence testing.  However, during early stage 
process development, there is little to no time to qualify scale down models for each cell line as speed to the 
clinic is the key imperative.  As such, most companies leverage the same platform SDM for the majority of the 
pipeline programs.  It is typical that only a single clone screen experiment is executed during this phase prior to 
the process being scaled up for clinical manufacturing.  As such, it is critical that the SDM at this stage is 
predictive of the clinical scale, particularly the product quality. 
 
This case study highlights an early phase program where as the process was scaled up, a significant increase in 
sequence variants was detected that was not observed in the SDM.  This prompted further SDM experiments to 
understand this phenomenon.  The root cause was identified to be minor differences in total feed volume 
delivered between the SDM and the at-scale run.  This was because sampling of the SDM bioreactors removes 
a greater proportion of the total bioreactor volume, relative to large scale bioreactors.  This minor difference had 
otherwise no impact to the cell culture performance or other product quality attributes.  Due to these data and 
experience, the process platform was updated to further improve our SDM. 
 
 
 
 
